$ROIV
Roivant Sciences Ltd.

2023 Q3 Form 10-Q Financial Statement

#000114036123039406 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $37.10M $21.62M $4.319M
YoY Change 196.03% 400.67% -44.16%
Cost Of Revenue $3.270M $4.214M $1.726M
YoY Change -10.19% 144.15% 132.61%
Gross Profit $33.84M $17.41M $2.593M
YoY Change 280.57% 571.42% -62.92%
Gross Profit Margin 91.21% 80.51% 60.04%
Selling, General & Admin $164.4M $156.2M $149.1M
YoY Change 4.24% 4.77% 80.14%
% of Gross Profit 485.68% 897.13% 5749.02%
Research & Development $132.0M $125.1M $135.8M
YoY Change -0.01% -7.88% 73.0%
% of Gross Profit 390.02% 718.74% 5238.33%
Depreciation & Amortization $5.600M $5.839M $2.678M
YoY Change -27.77% 118.04%
% of Gross Profit 16.55% 33.54% 103.28%
Operating Expenses $313.6M $298.0M $286.6M
YoY Change 6.91% 3.98% 76.8%
Operating Profit -$276.5M -$276.4M -$282.3M
YoY Change -1.54% -2.09% 82.86%
Interest Expense $9.247M $8.912M $2.612M
YoY Change -116.13% 241.19% 3.94%
% of Operating Profit
Other Income/Expense, Net -$5.931M $4.593M -$1.716M
YoY Change -31.15% -367.66% -1380.6%
Pretax Income -$327.4M -$326.1M -$349.8M
YoY Change 4.34% -6.77% 246.37%
Income Tax $3.757M $1.752M $3.999M
% Of Pretax Income
Net Earnings -$304.3M -$291.8M -$331.8M
YoY Change 4.37% -12.05% 303.74%
Net Earnings / Revenue -820.27% -1349.5% -7682.54%
Basic Earnings Per Share -$0.40 -$0.38 -$0.48
Diluted Earnings Per Share -$0.40 -$0.38 -$0.48
COMMON SHARES
Basic Shares Outstanding 771.7M 766.8M 695.9M
Diluted Shares Outstanding 770.2M 759.3M 695.9M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.408B $1.434B $1.942B
YoY Change -11.93% -26.16% -2.73%
Cash & Equivalents $1.408B $1.434B $1.942B
Short-Term Investments
Other Short-Term Assets $143.4M $127.1M $93.27M
YoY Change 28.21% 36.23% 68.16%
Inventory $4.905M $4.225M
Prepaid Expenses $60.72M $64.66M
Receivables $52.10M $37.06M
Other Receivables $2.500M $2.850M
Total Short-Term Assets $1.552B $1.561B $2.039B
YoY Change -9.52% -23.45% -0.88%
LONG-TERM ASSETS
Property, Plant & Equipment $24.48M $36.27M $31.69M
YoY Change -37.51% 14.46% -60.74%
Goodwill
YoY Change
Intangibles $140.6M $145.0M $145.4M
YoY Change 0.23% -0.27%
Long-Term Investments $250.4M $296.2M $301.3M
YoY Change 1.54% -1.67% 7.25%
Other Assets $49.80M $46.31M $12.82M
YoY Change 319.37% 261.21% -63.84%
Total Long-Term Assets $513.9M $575.5M $561.0M
YoY Change 2.65% 2.59% 41.27%
TOTAL ASSETS
Total Short-Term Assets $1.552B $1.561B $2.039B
Total Long-Term Assets $513.9M $575.5M $561.0M
Total Assets $2.066B $2.137B $2.600B
YoY Change -6.77% -17.83% 5.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $44.12M $50.04M $161.3M
YoY Change 6.69% -68.98% 974.36%
Accrued Expenses $152.9M $119.3M $109.4M
YoY Change 18.72% 9.12% 27.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $33.30M
YoY Change -100.0%
Long-Term Debt Due $49.00M $44.41M $33.30M
YoY Change 37.04% 33.34%
Total Short-Term Liabilities $265.5M $245.0M $328.9M
YoY Change 15.08% -25.51% 57.26%
LONG-TERM LIABILITIES
Long-Term Debt $389.4M $385.1M $383.7M
YoY Change 3.55% 0.35% 105.91%
Other Long-Term Liabilities $5.175M $16.90M $8.159M
YoY Change -43.16% 107.12% -89.72%
Total Long-Term Liabilities $5.175M $16.90M $8.159M
YoY Change -43.16% 107.12% -96.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $265.5M $245.0M $328.9M
Total Long-Term Liabilities $5.175M $16.90M $8.159M
Total Liabilities $739.9M $802.5M $822.5M
YoY Change 5.49% -2.43% 12.43%
SHAREHOLDERS EQUITY
Retained Earnings -$4.400B -$4.100B -$3.100B
YoY Change 29.9% 32.26%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $948.5M $910.7M $1.384B
YoY Change
Total Liabilities & Shareholders Equity $2.066B $2.137B $2.600B
YoY Change -6.77% -17.83% 5.94%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$304.3M -$291.8M -$331.8M
YoY Change 4.37% -12.05% 303.74%
Depreciation, Depletion And Amortization $5.600M $5.839M $2.678M
YoY Change -27.77% 118.04%
Cash From Operating Activities -$196.5M -$249.9M -$252.1M
YoY Change 3.62% -0.85% 78.57%
INVESTING ACTIVITIES
Capital Expenditures $300.0K $403.0K $7.459M
YoY Change -109.67% -94.6% 218.9%
Acquisitions
YoY Change
Other Investing Activities -$36.20M -$508.0K $0.00
YoY Change -74.82%
Cash From Investing Activities -$36.40M $105.0K -$7.459M
YoY Change -75.21% -101.41% 218.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 207.8M 7.477M 142.0M
YoY Change -2930.68% -94.73% 1290.56%
NET CHANGE
Cash From Operating Activities -196.5M -249.9M -252.1M
Cash From Investing Activities -36.40M 105.0K -7.459M
Cash From Financing Activities 207.8M 7.477M 142.0M
Net Change In Cash -25.10M -242.5M -117.6M
YoY Change -92.7% 106.24% -11.8%
FREE CASH FLOW
Cash From Operating Activities -$196.5M -$249.9M -$252.1M
Capital Expenditures $300.0K $403.0K $7.459M
Free Cash Flow -$196.8M -$250.3M -$259.5M
YoY Change 5.51% -3.55% 80.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 dei Amendment Flag
AmendmentFlag
false
CY2023Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2023Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q2 dei Entity Central Index Key
EntityCentralIndexKey
0001635088
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
21624000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4319000
CY2023Q2 roiv Operating Costs
OperatingCosts
4214000
CY2022Q2 roiv Operating Costs
OperatingCosts
1726000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125133000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
135830000
CY2023Q2 roiv Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
12500000
CY2022Q2 roiv Acquired In Process Research And Development Expense
AcquiredInProcessResearchAndDevelopmentExpense
0
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
156190000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149072000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
298037000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
286628000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-276413000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-282309000
CY2023Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-7564000
CY2022Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-24547000
CY2023Q2 roiv Gain Loss On Fair Value Of Debt And Liability Instruments
GainLossOnFairValueOfDebtAndLiabilityInstruments
-54512000
CY2022Q2 roiv Gain Loss On Fair Value Of Debt And Liability Instruments
GainLossOnFairValueOfDebtAndLiabilityInstruments
-41213000
CY2023Q2 roiv Interest Income
InterestIncome
16715000
CY2022Q2 roiv Interest Income
InterestIncome
1981000
CY2023Q2 us-gaap Interest Expense
InterestExpense
8912000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2612000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4593000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1085000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-326093000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-349785000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1752000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3999000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-327845000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-353784000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-36029000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-21975000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-291816000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-331809000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
759273550
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
759273550
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
695878859
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
695878859
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-327845000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-353784000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4148000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
5767000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4148000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5767000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-331993000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-348017000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-36184000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-22174000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-295809000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-325843000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1607587000
CY2023Q2 roiv Stock Issued During Period Value In Connection With Equity Incentive Plans And Tax Withholding Payments
StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
-14395000
CY2023Q2 roiv Stock Issued During Period Value Subsidiary Stock Options Exercised
StockIssuedDuringPeriodValueSubsidiaryStockOptionsExercised
890000
CY2023Q2 roiv Capital Contributions To Subsidiaries
CapitalContributionsToSubsidiaries
0
CY2023Q2 roiv Dividend Declared By Subsidiary
DividendDeclaredBySubsidiary
6000000
CY2023Q2 roiv Apic And Noncontrolling Interest Share Based Payment Arrangement Increase For Cost Recognition
APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
49260000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4148000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-327845000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1334139000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2038943000
CY2022Q2 roiv Issuance Of Subsidiary Common Shares To The Company Value
IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
0
CY2022Q2 roiv Stock Issued During Period Value In Connection With Equity Incentive Plans And Tax Withholding Payments
StockIssuedDuringPeriodValueInConnectionWithEquityIncentivePlansAndTaxWithholdingPayments
8329000
CY2022Q2 roiv Stock Issued During Period Value Common Shares Related To Settlement Of Transaction Consideration
StockIssuedDuringPeriodValueCommonSharesRelatedToSettlementOfTransactionConsideration
0
CY2022Q2 roiv Apic And Noncontrolling Interest Share Based Payment Arrangement Increase For Cost Recognition
APICAndNoncontrollingInterestShareBasedPaymentArrangementIncreaseForCostRecognition
72794000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5767000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-353784000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1755391000
CY2023Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21028000
CY2022Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2023Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
6000000
CY2022Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
0
CY2023Q2 roiv Intangible Assets Recorded In Accounts Payable
IntangibleAssetsRecordedInAccountsPayable
0
CY2022Q2 roiv Intangible Assets Recorded In Accounts Payable
IntangibleAssetsRecordedInAccountsPayable
146172000
CY2023Q2 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1400000000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4100000000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-327800000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-353800000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1434093000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1676813000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
5264000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
5011000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10291000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10291000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1449648000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1692115000
CY2023Q2 roiv Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
16800000
CY2023Q1 roiv Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
17569000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25446000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18096000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
119329000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
167129000
CY2023Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y3M18D
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
155284000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10247000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
145037000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
7100000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
9500000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
9500000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
9500000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
9500000
CY2023Q2 roiv Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
100100000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
64658000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
60827000
CY2023Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
37064000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
30379000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
5264000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
5011000
CY2023Q2 us-gaap Inventory Net
InventoryNet
4225000
CY2023Q1 us-gaap Inventory Net
InventoryNet
2761000
CY2023Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2850000
CY2023Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2356000
CY2023Q2 roiv Other Of Other Assets Current
OtherOfOtherAssetsCurrent
13004000
CY2023Q1 roiv Other Of Other Assets Current
OtherOfOtherAssetsCurrent
20440000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
127065000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
121774000
CY2023Q2 roiv Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
57160000
CY2023Q1 roiv Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
76278000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19923000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
55186000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10569000
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
12444000
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
1244000
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
542000
CY2023Q2 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
8073000
CY2023Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
2090000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
19886000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15076000
CY2023Q2 roiv Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
3
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.005
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001140361-23-039406-index-headers.html Edgar Link pending
0001140361-23-039406-index.html Edgar Link pending
0001140361-23-039406.txt Edgar Link pending
0001140361-23-039406-xbrl.zip Edgar Link pending
brhc20057263_10q.htm Edgar Link pending
brhc20057263_ex31-1.htm Edgar Link pending
brhc20057263_ex31-2.htm Edgar Link pending
brhc20057263_ex32-1.htm Edgar Link pending
brhc20057263_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
brhc20057263_10q_htm.xml Edgar Link completed
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
roiv-20230630.xsd Edgar Link pending
Show.js Edgar Link pending
roiv-20230630_lab.xml Edgar Link unprocessable
roiv-20230630_def.xml Edgar Link unprocessable
roiv-20230630_cal.xml Edgar Link unprocessable
roiv-20230630_pre.xml Edgar Link unprocessable